US 10544418
RNAi inhibition of alpha-ENaC expression
granted A61KA61K31/713A61K45/06
Quick answer
US patent 10544418 (RNAi inhibition of alpha-ENaC expression) held by Arrowhead Pharmaceuticals, Inc. expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K31/713, A61K45/06, A61P, A61P11/00